SCHEMBL14719178

SCHEMBL14719178

COC(=O)c1cc(F)cc(CBr)c1CBr

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ LMNA P02545 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ PLA2G2A P14555 1/20 0.36
▸ SOS1 Q07889 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA7 P43166 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ CA14 Q9ULX7 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ PDK4 Q16654 1/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20766650 0.86 KDM4E (0.42) KDM4EALDH1A1SLC6A4SLC6A3PLA2G2A
SCHEMBL18878157 0.85 CES2 (0.39) KDM4EALDH1A1LMNASLC6A4SLC6A3
SCHEMBL3410570 0.84 SOS1 (0.41) KDM4EALDH1A1SLC6A4SLC6A3SOS1
SCHEMBL30296812 0.84 SOS1 (0.41) KDM4EALDH1A1SLC6A4SLC6A3SOS1
SCHEMBL31169205 0.84 KDM4E (0.37) KDM4EALDH1A1LMNASLC6A4SLC6A3
SCHEMBL21001493 0.83 GAA (0.39) KDM4EALDH1A1LMNASLC6A4SLC6A3
SCHEMBL30810255 0.83 KDM4E (0.43) KDM4EALDH1A1LMNASLC6A4SLC6A3
SCHEMBL21509656 0.82 NR4A2 (0.38) KDM4EALDH1A1LMNASLC6A3CA12
SCHEMBL17724094 0.81 PLA2G2A (0.32) ALDH1A1PLA2G2ASOS1HPGDSMN1; SMN2
SCHEMBL21932876 0.80 SLC6A4 (0.34) KDM4EALDH1A1LMNASLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053365-A1 DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) BIOMARIN PHARMACEUTICAL, INC. (US) 2013-02-28 — — US disclosed
US-20130053365-A1 DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) BIOMARIN PHARMACEUTICAL, INC. (US) 2013-02-28 — — US disclosed
US-20130053365-A1 DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) BIOMARIN PHARMACEUTICAL, INC. (US) 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053365-A1 DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) PARP1, PARP2, PARP3 KDM4E 1587/4885ALDH1A1 328/4885LMNA 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback